Join
Live feed
·
PRReleasevia Quantisnow
Caribou Biosciences Inc. logo

Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
CRBU· Caribou Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRBU (Caribou Biosciences Inc.) and more on Quantisnow.